Amgen (AMGN)
As of Nov 11, 2026, Kalshi has settled 14 word markets on Amgen’s earnings calls since 2026, on 14 different words. Next call: Feb 2, 2027 (15 words listed).
| Word | Q4’24Feb '25 | Q1’25May '25 | Q2’25Aug '25 | Q3’25Nov '25 | Q4’25year ago | Q1’26Apr '26 | Q2’26Aug '26 | Q3’26last call | Trend | Last 8 | Scripted | All-time | Probability | Market |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLP-1 / GLP | 0 times: GLP-1 / GLP, Q4’24 Feb '25 | 3 times: GLP-1 / GLP, Q1’25 May '25, counts as said | 0 times: GLP-1 / GLP, Q2’25 Aug '25 | 1 time: GLP-1 / GLP, Q3’25 Nov '25, counts as said | 1 time: GLP-1 / GLP, Q4’25 Feb '26, counts as said | 7 times: GLP-1 / GLP, Q1’26 Apr '26, counts as said | 6 times: GLP-1 / GLP, Q2’26 Aug '26, counts as said | 4 times: GLP-1 / GLP, Q3’26 Nov '26, counts as said | rising | 6/875% | 4/850% | 14/8317% | 85%n=1+tx from settlement history blended with transcripts | 78¢ Kalshi |
| Dazodalibep | 0 times: Dazodalibep, Q4’24 Feb '25 | 0 times: Dazodalibep, Q1’25 May '25 | 0 times: Dazodalibep, Q2’25 Aug '25 | 0 times: Dazodalibep, Q3’25 Nov '25 | 0 times: Dazodalibep, Q4’25 Feb '26 | 3 times: Dazodalibep, Q1’26 Apr '26, counts as said | 10 times: Dazodalibep, Q2’26 Aug '26, counts as said | 9 times: Dazodalibep, Q3’26 Nov '26, counts as said | rising | 3/838% | 3/838% | 6/837% | 83%n=1+tx from settlement history blended with transcripts | 82¢ Kalshi |
| VESALIUS-CV | 1 time: VESALIUS-CV, Q4’24 Feb '25, counts as said | 0 times: VESALIUS-CV, Q1’25 May '25 | 1 time: VESALIUS-CV, Q2’25 Aug '25, counts as said | 8 times: VESALIUS-CV, Q3’25 Nov '25, counts as said | 2 times: VESALIUS-CV, Q4’25 Feb '26, counts as said | 6 times: VESALIUS-CV, Q1’26 Apr '26, counts as said | 3 times: VESALIUS-CV, Q2’26 Aug '26, counts as said | 1 time: VESALIUS-CV, Q3’26 Nov '26, counts as said | rising | 7/888% | 5/862% | 7/838% | 79%transcripts from the transcript model | 60¢ Kalshi |
| Eosinophilic | 1 time: Eosinophilic, Q4’24 Feb '25, counts as said | 0 times: Eosinophilic, Q1’25 May '25 | 1 time: Eosinophilic, Q2’25 Aug '25, counts as said | 2 times: Eosinophilic, Q3’25 Nov '25, counts as said | 2 times: Eosinophilic, Q4’25 Feb '26, counts as said | 0 times: Eosinophilic, Q1’26 Apr '26 | 1 time: Eosinophilic, Q2’26 Aug '26, counts as said | 6 times: Eosinophilic, Q3’26 Nov '26, counts as said | rising | 6/875% | 6/875% | 16/8319% | 76%n=1+tx from settlement history blended with transcripts | 74¢ Kalshi |
| ESMO | 0 times: ESMO, Q4’24 Feb '25 | 0 times: ESMO, Q1’25 May '25 | 0 times: ESMO, Q2’25 Aug '25 | 2 times: ESMO, Q3’25 Nov '25, counts as said | 0 times: ESMO, Q4’25 Feb '26 | 0 times: ESMO, Q1’26 Apr '26 | 0 times: ESMO, Q2’26 Aug '26 | 5 times: ESMO, Q3’26 Nov '26, counts as said | rising | 2/825% | 1/812% | 9/8311% | 59%n=1+tx from settlement history blended with transcripts | 18¢ Kalshi |
| Imfinzi / Durvalumab | 0 times: Imfinzi / Durvalumab, Q4’24 Feb '25 | 1 time: Imfinzi / Durvalumab, Q1’25 May '25, counts as said | 0 times: Imfinzi / Durvalumab, Q2’25 Aug '25 | 0 times: Imfinzi / Durvalumab, Q3’25 Nov '25 | 0 times: Imfinzi / Durvalumab, Q4’25 Feb '26 | 0 times: Imfinzi / Durvalumab, Q1’26 Apr '26 | 0 times: Imfinzi / Durvalumab, Q2’26 Aug '26 | 5 times: Imfinzi / Durvalumab, Q3’26 Nov '26, counts as said | rising | 2/825% | 2/825% | 2/832% | 59%n=1+tx from settlement history blended with transcripts | 42¢ Kalshi |
| Medicare | 0 times: Medicare, Q4’24 Feb '25 | 0 times: Medicare, Q1’25 May '25 | 0 times: Medicare, Q2’25 Aug '25 | 0 times: Medicare, Q3’25 Nov '25 | 0 times: Medicare, Q4’25 Feb '26 | 0 times: Medicare, Q1’26 Apr '26 | 2 times: Medicare, Q2’26 Aug '26, counts as said | 1 time: Medicare, Q3’26 Nov '26, counts as said | rising | 2/825% | 1/812% | 35/8342% | 52%n=1+tx from settlement history blended with transcripts | 35¢ Kalshi |
| Tavneos | 1 time: Tavneos, Q4’24 Feb '25, counts as said | 3 times: Tavneos, Q1’25 May '25, counts as said | 0 times: Tavneos, Q2’25 Aug '25 | 3 times: Tavneos, Q3’25 Nov '25, counts as said | 3 times: Tavneos, Q4’25 Feb '26, counts as said | 4 times: Tavneos, Q1’26 Apr '26, counts as said | 0 times: Tavneos, Q2’26 Aug '26 | 0 times: Tavneos, Q3’26 Nov '26 | falling | 5/862% | 4/850% | 16/8319% | 50%n=1+tx from settlement history blended with transcripts | 36¢ Kalshi |
| Oral3+ times | 1 time: Oral (3+ times), Q4’24 Feb '25, below the threshold | 9 times: Oral (3+ times), Q1’25 May '25, counts as said | 3 times: Oral (3+ times), Q2’25 Aug '25, counts as said | 2 times: Oral (3+ times), Q3’25 Nov '25, below the threshold | 6 times: Oral (3+ times), Q4’25 Feb '26, counts as said | 2 times: Oral (3+ times), Q1’26 Apr '26, below the threshold | 3 times: Oral (3+ times), Q2’26 Aug '26, counts as said | 1 time: Oral (3+ times), Q3’26 Nov '26, below the threshold | falling | 4/850% | 0/80% | 23/8328% | 34%n=1+tx from settlement history blended with transcripts | 49¢ Kalshi |
| Acquisition | 5 times: Acquisition, Q4’24 Feb '25, counts as said | 2 times: Acquisition, Q1’25 May '25, counts as said | 1 time: Acquisition, Q2’25 Aug '25, counts as said | 1 time: Acquisition, Q3’25 Nov '25, counts as said | 0 times: Acquisition, Q4’25 Feb '26 | 0 times: Acquisition, Q1’26 Apr '26 | 1 time: Acquisition, Q2’26 Aug '26, counts as said | 0 times: Acquisition, Q3’26 Nov '26 | falling | 5/862% | 3/838% | 54/8365% | 27%n=1+tx from settlement history blended with transcripts | 28¢ Kalshi |
| Litigation | 0 times: Litigation, Q4’24 Feb '25 | 0 times: Litigation, Q1’25 May '25 | 0 times: Litigation, Q2’25 Aug '25 | 0 times: Litigation, Q3’25 Nov '25 | 0 times: Litigation, Q4’25 Feb '26 | 2 times: Litigation, Q1’26 Apr '26, counts as said | 0 times: Litigation, Q2’26 Aug '26 | 0 times: Litigation, Q3’26 Nov '26 | rising | 1/812% | 1/812% | 27/8333% | 24%n=1+tx from settlement history blended with transcripts | 16¢ Kalshi |
| Artificial Intelligence3+ times | 2 times: Artificial Intelligence (3+ times), Q4’24 Feb '25, below the threshold | 1 time: Artificial Intelligence (3+ times), Q1’25 May '25, below the threshold | 1 time: Artificial Intelligence (3+ times), Q2’25 Aug '25, below the threshold | 1 time: Artificial Intelligence (3+ times), Q3’25 Nov '25, below the threshold | 0 times: Artificial Intelligence (3+ times), Q4’25 Feb '26 | 5 times: Artificial Intelligence (3+ times), Q1’26 Apr '26, counts as said | 2 times: Artificial Intelligence (3+ times), Q2’26 Aug '26, below the threshold | 1 time: Artificial Intelligence (3+ times), Q3’26 Nov '26, below the threshold | rising | 1/812% | 1/812% | 2/832% | 21%n=1+tx from settlement history blended with transcripts | 16¢ Kalshi |
| Patent2+ times | 1 time: Patent (2+ times), Q4’24 Feb '25, below the threshold | 0 times: Patent (2+ times), Q1’25 May '25 | 0 times: Patent (2+ times), Q2’25 Aug '25 | 1 time: Patent (2+ times), Q3’25 Nov '25, below the threshold | 0 times: Patent (2+ times), Q4’25 Feb '26 | 3 times: Patent (2+ times), Q1’26 Apr '26, counts as said | 1 time: Patent (2+ times), Q2’26 Aug '26, below the threshold | 0 times: Patent (2+ times), Q3’26 Nov '26 | rising | 1/812% | 1/812% | 15/8318% | 19%n=1+tx from settlement history blended with transcripts | 18¢ Kalshi |
| Prolia2+ times | 3 times: Prolia (2+ times), Q4’24 Feb '25, counts as said | 1 time: Prolia (2+ times), Q1’25 May '25, below the threshold | 1 time: Prolia (2+ times), Q2’25 Aug '25, below the threshold | 2 times: Prolia (2+ times), Q3’25 Nov '25, counts as said | 1 time: Prolia (2+ times), Q4’25 Feb '26, below the threshold | 1 time: Prolia (2+ times), Q1’26 Apr '26, below the threshold | 1 time: Prolia (2+ times), Q2’26 Aug '26, below the threshold | 0 times: Prolia (2+ times), Q3’26 Nov '26 | falling | 2/825% | 1/812% | 56/8367% | 19%n=1+tx from settlement history blended with transcripts | 23¢ Kalshi |
| Buyback / Buy Back | 0 times: Buyback / Buy Back, Q4’24 Feb '25 | 0 times: Buyback / Buy Back, Q1’25 May '25 | 0 times: Buyback / Buy Back, Q2’25 Aug '25 | 0 times: Buyback / Buy Back, Q3’25 Nov '25 | 0 times: Buyback / Buy Back, Q4’25 Feb '26 | 0 times: Buyback / Buy Back, Q1’26 Apr '26 | 0 times: Buyback / Buy Back, Q2’26 Aug '26 | 0 times: Buyback / Buy Back, Q3’26 Nov '26 | steady | 0/80% | 0/80% | 31/8337% | 12%n=1+tx from settlement history blended with transcripts | 12¢ Kalshi |
- times said on that call
- counted as said (ring)
- no call
- probability next time, with n
- Select a word or a cell for its quotes
What the columns mean
- Last N
- of the appearances shown, how many counted as said
- Trend
- how the count moved over these calls
- Scripted
- calls of the last 8 where it was said in the prepared remarks
- All-time
- every call on file
- Probability
- the calibrated probability for the next listing; n is the settled observations behind it when it was computed, '+tx' adds the transcripts, 'new' means too little history
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Nov 4, 2026 01:31 UTC.
Appearances and settled record
latest 12 earnings callsOur transcript counts matched how 14 of 14 settled words resolved (100.0%). How we check.
| Date | Appearance | Text | Words | Settled | Our count agreed |
|---|---|---|---|---|---|
| Nov 3, 2026 | Earnings call FY26 Q3 | Speaker-labelled transcript | 14 | 6 yes · 8 no | 14/14 (100%) |
| Aug 4, 2026 | Earnings call FY26 Q2 | Speaker-labelled transcript | 0 | – | – |
| Apr 30, 2026 | Earnings call FY26 Q1 | Speaker-labelled transcript | 0 | – | – |
| Feb 3, 2026 | Earnings call FY25 Q4 | Speaker-labelled transcript | 0 | – | – |
| Nov 4, 2025 | Earnings call FY25 Q3 | Speaker-labelled transcript | 0 | – | – |
| Aug 5, 2025 | Earnings call FY25 Q2 | Speaker-labelled transcript | 0 | – | – |
| May 1, 2025 | Earnings call FY25 Q1 | Speaker-labelled transcript | 0 | – | – |
| Feb 4, 2025 | Earnings call FY24 Q4 | Speaker-labelled transcript | 0 | – | – |
| Oct 30, 2024 | Earnings call FY24 Q3 | Speaker-labelled transcript | 0 | – | – |
| Aug 6, 2024 | Earnings call FY24 Q2 | Speaker-labelled transcript | 0 | – | – |
| May 2, 2024 | Earnings call FY24 Q1 | Speaker-labelled transcript | 0 | – | – |
| Feb 6, 2024 | Earnings call FY23 Q4 | Speaker-labelled transcript | 0 | – | – |
Citeparrot.markets, “Amgen (AMGN): earnings call word history”, as of Nov 11, 2026, https://parrot.markets/earnings/AMGN (CC BY 4.0)
Agents: this page as TSV at /api/v1/entity/amgen · words: /api/v1/history?entity=amgen · columnar JSON in #parrot-data · llms.txt · MCP